Austin Institute for Clinical Research

Pflugerville, Texas 78860

2 studies enrolling now · 38 studies all time

What they study most

Acne Vulgaris, Actinic Keratosis (AK), Active Nonsegmental Vitiligo, Alopecia Areata, Alopecia, Androgenetic, Atopic Dermatitis, CTCL, CTCL/ Mycosis Fungoides, Cellulite, Chronic Inducible Urticaria, Chronic Plaque Psoriasis, Chronic Spontaneous Urticaria

Studies at this site

• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Recruiting now
• Evaluate RLS-1496 Topical Cream for Actinic Keratosis — Recruiting now
• Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Completed
• Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL — Stopped early
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) — Running, not enrolling
• Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis — Completed
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata — Running, not enrolling
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight — Completed
• A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria — Completed
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata — Completed
• A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) — Completed
• A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis — Running, not enrolling
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Candin for the Treatment of Common Warts — Completed
• Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon — Completed
• Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype — Completed
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy — Completed
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis — Completed
• Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea — Completed
• A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis — Stopped early
• A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) — Completed
• A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis — Completed
• Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis — Completed
• Study of Glycopyrronium in Axillary Hyperhydrosis — Completed
• A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris — Completed
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma — Stopped early
• EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) — Completed
• Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris — Completed